Biospecimen Collection (NCT07275216)

Name: Biospecimen Collection trial for Classic Hodgkin Lymphoma (NCT07275216)
Uploaded: 2026-10-31T15:18:54.699Z
Duration: 1 min 19 s
Description: Biospecimen Collection trial for Classic Hodgkin Lymphoma (NCT07275216). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07275216.

Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment: a one-minute explainerNCT072752161 min

Biospecimen Collection trial for Classic Hodgkin Lymphoma (NCT07275216). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with untreated classic Hodgkin lymphoma who cannot receive anthracycline chemotherapy because of age, function, or organ health. Age is one qualifying route.

The idea: pembrolizumab releases an immune brake; gemcitabine interferes with DNA production. Both are infused every three weeks for up to eight cycles. Patients without progression can receive pembrolizumab maintenance. Eligible patients with progression switch to pembrolizumab, brentuximab vedotin, and dacarbazine. Researchers measure metabolic responses.

This phase 2 study plans 23 patients. Matthew Mei leads at City of Hope in Duarte, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.